The history behind the use of antipsychotic medications in persons with intellectual disability: Part I

Mental Health Aspects of Developmental Disabilities

Volumn 9, Issue 1, 2006, Pages 26-32

  Levitas, Andrew S ^a,c   Hurley, Anne DesNoyers ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UMDNJ School of Osteopathic Medicine   (United States)

Author keywords

Antipsychotic medication; Developmental disabilities; Intellectual disability; Mental retardation; Psychiatric disorder; Tardive dyskinesia

Indexed keywords

ACETYLCHOLINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DOPAMINE; NEUROLEPTIC AGENT; NORADRENALIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

ARTICLE; BLOOD DYSCRASIA; CATATONIA; DELUSION; DEVELOPMENTAL DISORDER; DRUG MISUSE; DRUG USE; DYSTONIA; HALLUCINATION; HISTORY OF MEDICINE; HUMAN; HYPERPYREXIA; INTELLECTUAL IMPAIRMENT; MENTAL DEFICIENCY; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PROGNOSIS; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREMOR;

EID: 33745954212     PISSN: 10573291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. American Psychiatrie Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: Author, 1980.
2. Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. J Ment Defic Res 1985;29:187-195.
3. Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Weiiropsychopliarmacol Biol Psychiatry 1995;19:1323-1334.
4. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch Gen Psychiatry 1995;52:173-188.
5. Gold JM, Egan MF, Kirch DG, et al. Tardive dyskinesia: Neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol Psychiatry 1991;30:587-599.
6. Goldman MB, Luchins DJ. Intermittent neuroleptic therapy and tardive dyskinesia: A literature review. Hosp Community Psychiatry 1984;35:1215-1219.
7. Inoue F. Neuroleptic withdrawal behavior-Cases of rebound cholinergic supersensitivity. Clin Pharm 1982;1:567-569.
8. Jeste DV, Potkin SG, Sinha S, Feder S, Wyatt RJ. Tardive dyskinesia-Reversible and persistent. Arch Gen Psychiatry 1979;36:585-590.
9. Jus A, Jus K, Fontaine P. Long term treatment of tardive dyskinesia. J Clin Psychiatry 1979;40:72-77.
10. Levitas A, Reid CS. Rubinstein-Taybi syndrome and psychiatric disorders. J Intellect Disabil Res 1998;42:284-292.
11. Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes. Psychosomatics 1981;22:253-254.
12. Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes. J Clin Psychiatry 1981;42:179.
13. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980;137:1395-1398.
14. Mikkelsen EJ, Albert LG, Upadhyaya A. Neuroleptic-withdrawal cachexia. N Engl J Med 1988;318:929.
15. Schonecker M. Ein eigentumliches Syndrom im oralen Bereich bei Megaphenapplikation. Nervenarzt 1957;28:35.
16. Smith RC. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Arch Gen Psychiatry 1994;51:427-429.
17. Sovner R. Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: Two case reports. Ment Retard 1995;33:221-225.
18. Weiner WJ, Luby ED. Persistent akathisia following neuroleptic withdrawal. Ann Neurol 1983;13:466-467.
19. Witschy JK, Malone GL, Holden LD. Psychosis after neuroleptic withdrawal in a manic-depressive patient. Am J Psychiatry 1984;141:105-106.
20. Yassa R, Nair V, Schwartz G. Tardive dyskinesia: A two-year follow-up study. Psychosomatics 1984;25:852-855.